MX2011007663A - Compuestos de sulfona heterociclica, saturada y sustituida en n, con actividad agonistica del receptor de cb2. - Google Patents
Compuestos de sulfona heterociclica, saturada y sustituida en n, con actividad agonistica del receptor de cb2.Info
- Publication number
- MX2011007663A MX2011007663A MX2011007663A MX2011007663A MX2011007663A MX 2011007663 A MX2011007663 A MX 2011007663A MX 2011007663 A MX2011007663 A MX 2011007663A MX 2011007663 A MX2011007663 A MX 2011007663A MX 2011007663 A MX2011007663 A MX 2011007663A
- Authority
- MX
- Mexico
- Prior art keywords
- saturated heterocyclic
- substituted saturated
- agonistic activity
- sulfone compounds
- receptor agonistic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Esta invención se refiere a compuestos de la fórmula (I) o una sal farmacéuticamente aceptable de éste, en donde, X, R1, R2, R3, R4, R5, R6, R7, k, m, n, p, q, r y s son cada una como se describe aquí, y las composiciones que contienen tales compuestos, y el uso de tales compuestos en el tratamiento de una condición mediada por la actividad del receptor de CB2. (ver fórmula (I)).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20203609P | 2009-01-22 | 2009-01-22 | |
US21397709P | 2009-08-04 | 2009-08-04 | |
PCT/JP2010/000377 WO2010084767A1 (en) | 2009-01-22 | 2010-01-22 | N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011007663A true MX2011007663A (es) | 2011-08-15 |
Family
ID=42355822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011007663A MX2011007663A (es) | 2009-01-22 | 2010-01-22 | Compuestos de sulfona heterociclica, saturada y sustituida en n, con actividad agonistica del receptor de cb2. |
Country Status (10)
Country | Link |
---|---|
US (1) | US8653063B2 (es) |
EP (1) | EP2379533A4 (es) |
JP (1) | JP5816883B2 (es) |
KR (1) | KR20110117146A (es) |
CN (1) | CN102292328A (es) |
BR (1) | BRPI1007202A2 (es) |
CA (1) | CA2747801A1 (es) |
MX (1) | MX2011007663A (es) |
RU (1) | RU2011134868A (es) |
WO (1) | WO2010084767A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
WO2012090179A2 (en) | 2010-12-30 | 2012-07-05 | Lupin Limited | Isoquinoline derivatives as cannabinoid receptor modulators |
WO2012090177A2 (en) | 2010-12-30 | 2012-07-05 | Lupin Limited | Cannabinoid receptor modulators |
CN102276511A (zh) * | 2011-06-20 | 2011-12-14 | 兰州博实生化科技有限责任公司 | 1-叔丁氧羰基-3-碘氮杂环丁烷的合成方法 |
WO2013005168A2 (en) | 2011-07-05 | 2013-01-10 | Lupin Limited | Cannabinoid receptor modulators |
CN102432514B (zh) * | 2011-12-26 | 2014-05-07 | 兰州博实生化科技有限责任公司 | 1-叔丁氧羰基-3-氟氮杂环丁烷的合成方法 |
US8633182B2 (en) | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
EP3563849A3 (en) | 2012-10-25 | 2020-02-12 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
EP3060205A4 (en) | 2013-10-22 | 2017-06-28 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
CA3033079A1 (en) | 2016-08-31 | 2018-03-08 | The General Hospital Corporation | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases |
WO2019017995A1 (en) | 2017-07-20 | 2019-01-24 | Aztherapies, Inc. | FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN |
CN113038944A (zh) | 2018-07-02 | 2021-06-25 | 通用医疗公司 | 色甘酸钠和α-乳糖的粉末化制剂 |
IL301333A (en) * | 2020-11-12 | 2023-05-01 | Askat Inc | Stable salt and crystal forms of (2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-H1-1,3-benzodiazol-5-yl}sulfonyl)aztidine- 1-Yil]Ethan-1-Wol |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2751649B1 (fr) * | 1996-07-26 | 1998-08-28 | Adir | Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
DE602005011844D1 (de) | 2004-11-02 | 2009-01-29 | Pfizer | Sulfonylbenzimidazolderivate |
JP2009536918A (ja) | 2006-03-06 | 2009-10-22 | ファイザー株式会社 | スルホニルベンゾイミダゾール誘導体 |
MX2009000149A (es) * | 2006-07-04 | 2009-01-23 | Janssen Pharmaceutica Nv | Agonistas de bencimidazol canabinoide que portan un grupo heterociclico sustituido. |
EP2142531B1 (en) | 2007-03-30 | 2015-07-08 | Janssen Pharmaceutica N.V. | Benzimidazole cannabinoid agonists |
ES2574130T3 (es) * | 2007-12-17 | 2016-06-15 | Janssen Pharmaceutica, N.V. | Bencimidazoles sustituidos con fluoroalquilo como agonistas cannabinoides |
-
2010
- 2010-01-22 CA CA2747801A patent/CA2747801A1/en not_active Abandoned
- 2010-01-22 WO PCT/JP2010/000377 patent/WO2010084767A1/en active Application Filing
- 2010-01-22 EP EP10733374A patent/EP2379533A4/en not_active Withdrawn
- 2010-01-22 RU RU2011134868/04A patent/RU2011134868A/ru unknown
- 2010-01-22 CN CN2010800053579A patent/CN102292328A/zh active Pending
- 2010-01-22 US US13/145,439 patent/US8653063B2/en active Active
- 2010-01-22 KR KR1020117018693A patent/KR20110117146A/ko not_active Application Discontinuation
- 2010-01-22 BR BRPI1007202A patent/BRPI1007202A2/pt not_active IP Right Cessation
- 2010-01-22 MX MX2011007663A patent/MX2011007663A/es not_active Application Discontinuation
- 2010-01-22 JP JP2011526737A patent/JP5816883B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
KR20110117146A (ko) | 2011-10-26 |
BRPI1007202A2 (pt) | 2016-02-23 |
US8653063B2 (en) | 2014-02-18 |
EP2379533A1 (en) | 2011-10-26 |
WO2010084767A1 (en) | 2010-07-29 |
JP5816883B2 (ja) | 2015-11-18 |
CN102292328A (zh) | 2011-12-21 |
US20110281840A1 (en) | 2011-11-17 |
CA2747801A1 (en) | 2010-07-29 |
EP2379533A4 (en) | 2012-07-04 |
RU2011134868A (ru) | 2013-02-27 |
JP2012515712A (ja) | 2012-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011007663A (es) | Compuestos de sulfona heterociclica, saturada y sustituida en n, con actividad agonistica del receptor de cb2. | |
MX2009008284A (es) | Compuestos triciclicos y su uso como moduladores de receptor de glucocorticoides. | |
UY29184A1 (es) | Derivados de sulfonilbencimidazol | |
PH12014502597A1 (en) | N-substituted benzamides and their use in the treatment of pain | |
IN2012DN01233A (es) | ||
GEP20115140B (en) | Substituted spirocyclic cgrp receptor antagonists | |
PT2310356E (pt) | Derivados de adamantildiamida e a sua utilização | |
MY149648A (en) | Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament | |
MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
NZ705135A (en) | Heteroaryl compounds and methods of use thereof | |
MY169043A (en) | New dihydroquinoline-2-one derivatives | |
MY162535A (en) | Inhibitors of arginase and their therapeutic applications | |
EA201000050A1 (ru) | Замещенные бициклолактамные соединения | |
MX2009003157A (es) | Pirazoliltienopiridinas terapeuticas. | |
GEP20094727B (en) | Oxyindole derivatives as 5ht4 receptor agonists | |
MX2012003644A (es) | Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila. | |
RS20090208A (en) | Pyrazoline compounds as mineralocorticoid receptor antagonists | |
EA201171211A1 (ru) | Производные оксадиазола | |
NZ703989A (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
MX2009012117A (es) | Composiciones y derivados heterociclicos sustituidos y su uso farmaceutico como antibacterianos. | |
MX2010002760A (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3. | |
MX2011006843A (es) | Dihidropiridona-amidas como moduladores de p2x7. | |
MX2009003645A (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3. | |
MY169267A (en) | New aryl-quinoline derivatives | |
EA201200602A1 (ru) | Индазолы и пиразолопиридины в качестве антагонистов рецептора ccr1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |